USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
CYNVENIO BIOSYSTEMS, INC.
Address:
2260 Townsgate Road
WESTLAKE VILLAGE, CA 91361-2437
Phone:
N/A
URL:
N/A
EIN:
127159223
DUNS:
827484655
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $477,167.00 3
SBIR Phase II $2,385,670.00 2

Award List:

System for Rapid Generation of Aptamers for Transplant Therapies

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$99,996.00
Agency:
HHS
Principal Investigator:
Karen Qian
Abstract:
DESCRIPTION (provided by applicant): Autologous hematopoietic stem cell transplantation (HSCT) has been an important treatment option for many patients with hematologic malignancies and solid tumors such as acute myeloid leukemia, myelodysplastic syndromes , chronic myeloid leukemia, systemic… More

TAS::75 0849::TAS SBIR TOPIC 277 - NOVEL CTC-BASED TEST FOR LUNG CANCER DRUG RESISTANCE

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$195,030.00
Agency:
HHS
Principal Investigator:
Paul Dempsey – 805-777-0017
Abstract:
The evolving understanding of cancer indicates every tumor has distinct characteristics driven by the molecular pathology of the disease. Predicted by this heterogeneity, targeted therapeutic agents are much more successful than a one size fits all approach. Currently, there are no tools to… More

TAS::75 0849::TAS TOPIC 293, A LIQUID BIOPSY TO ASSESS MUTATION IN LUNG CANCER

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$182,141.00
Agency:
HHS
Principal Investigator:
Paul Dempsey – 805-777-0017
Abstract:
Improvement of treatment outcomes for patients with solid tissue tumors depends on the drug s ability to target the genetic mutations responsible for tumor growth. Currently, mutational analysis requires an invasive tissue biopsy, which is clinically impractical to perform repeatedly. Alternatively,… More

Development of Pro-SELEX Aptamer Selection Platform

Award Year / Program / Phase:
2012 / SBIR / Phase II
Award Amount:
$1,387,762.00
Agency:
HHS
Principal Investigator:
Paul W. Dempsey – 805-214-6377
Abstract:
DESCRIPTION (provided by applicant): Aptamers are nucleic acid based affinity reagents that can be selected in vitro from large combinatorial libraries. As an affinity reagent they have inherent advantages as they are chemically synthesized, thermostable,immunologically neutral, significantly… More

SBIR Phase II Topic 293 Developing Predictive Biomarkers in Metastatic Breast Can

Award Year / Program / Phase:
2013 / SBIR / Phase II
Award Amount:
$997,908.00
Agency:
HHS
Principal Investigator:
Paul Dempsey – 805-777-0017
Abstract:
Not Available